The overall 5-year relative survival rate for female breast cancer in the United States is 91.9%, based on SEER data from 2016 to 2022. That means women diagnosed with breast cancer are, on average, about 92% as likely to be alive five years later as women in the general population. But that single number hides enormous variation. Your individual odds depend heavily on how far the cancer has spread, what type it is, and several other factors.
Survival Rates by How Far the Cancer Has Spread
Doctors categorize breast cancer by extent of spread: localized (still within the breast), regional (reached nearby lymph nodes or tissue), and distant (spread to organs like the lungs, liver, or bones). These categories matter far more than the single national average.
The 5-year relative survival rates break down like this:
- Localized: 99.3%. The cancer hasn’t left the breast tissue, and nearly everyone diagnosed at this stage survives at least five years.
- Regional: 86.3%. The cancer has reached nearby lymph nodes but hasn’t traveled to distant parts of the body.
- Distant (metastatic/stage IV): 31%. The cancer has spread to distant organs. This is the stage where survival drops most sharply.
These numbers come from the National Cancer Institute and reflect diagnoses made between 2013 and 2019. Treatments have continued to improve since then, so current outcomes for recently diagnosed patients may be somewhat better, particularly for metastatic disease where new targeted therapies have expanded options considerably.
Long-Term Survival Beyond Five Years
Five-year survival is the standard benchmark, but many people want to know what happens further out. The 10-year relative survival rate for breast cancer is 84%, and the 15-year rate is 80%, according to American Cancer Society data published by Moffitt Cancer Center. The gradual decline reflects a small but ongoing risk of late recurrence, particularly in certain cancer subtypes. Still, the vast majority of breast cancer survivors are alive and well more than a decade after diagnosis.
How Cancer Type Affects Your Odds
Not all breast cancers behave the same way. The biology of your specific tumor, particularly which receptors it carries, plays a major role in both treatment options and survival.
Triple-Negative Breast Cancer
Triple-negative breast cancer (TNBC) lacks three common receptors that many treatments target, making it harder to treat. It also tends to grow faster and is more likely to have spread by the time it’s found. The 5-year survival rates for TNBC are noticeably lower than for breast cancer overall: 92% for localized, 67% for regional, and 15% for distant disease. Across all stages combined, the rate is 78%.
HER2-Positive Breast Cancer
HER2-positive cancers overproduce a protein that fuels cell growth. Targeted therapies developed over the past two decades have dramatically improved outcomes for this subtype. For localized HER2-positive cancer, 5-year survival is 97% to 99%, depending on whether hormone receptors are also present. For regional disease, it’s 84% to 89%. Even for distant HER2-positive cancer, survival rates reach 39% to 45%, considerably higher than the 31% average for all metastatic breast cancers and far higher than for metastatic TNBC.
About half of HER2-positive breast cancers also carry hormone receptors, and those tend to have slightly better outcomes at every stage.
Why Early Detection Changes Everything
The gap between localized and distant survival (99.3% versus 31%) makes early detection one of the most powerful factors in breast cancer outcomes. When breast cancer is caught through routine screening before it causes symptoms, the 5-year relative survival rate exceeds 99%, according to the National Breast Cancer Foundation citing American Cancer Society data. That’s essentially the same survival rate as someone who never had cancer at all.
Cancers found after symptoms appear, such as a lump, skin changes, or nipple discharge, are more likely to have already spread, which shifts the odds. This is the core argument for regular mammography screening: catching cancer while it’s still localized keeps you in the highest survival category.
Recurrence Risk After Treatment
Surviving the initial treatment doesn’t completely eliminate the possibility of cancer returning. For women treated with lumpectomy and radiation therapy, the chance of recurrence within 10 years ranges from 3% to 15%. The specific risk depends on the original tumor’s size, grade, lymph node involvement, and molecular subtype.
TNBC is more likely to recur than hormone receptor-positive cancers, but its recurrences tend to happen within the first few years. Hormone receptor-positive cancers, by contrast, can recur much later, sometimes 10 or 15 years after the original diagnosis. This is one reason doctors sometimes recommend extended hormone-blocking therapy for five to ten years after initial treatment.
Racial and Ethnic Disparities in Outcomes
Survival rates are not equal across racial and ethnic groups in the U.S. Black women face a mortality rate of 24.2% compared to 15.6% for white women, a gap driven by multiple overlapping factors. Black women are nearly twice as likely to be diagnosed with triple-negative breast cancer (25% versus 13.6%) and more likely to have metastatic disease at the time of diagnosis (4.6% versus 3.2%). They also face higher recurrence rates: 14.9% compared to 12.1%.
Hispanic women are more likely to be diagnosed at higher stages and with larger tumors, though the differences are smaller. These disparities reflect a combination of unequal access to screening and timely treatment, differences in cancer biology, and systemic gaps in healthcare delivery. The biology alone doesn’t account for the full gap; studies consistently show that when Black and white women receive the same quality of care at the same stage, the survival difference narrows substantially.
What the Numbers Actually Mean for You
Survival statistics describe what happened to large groups of people diagnosed in prior years. They don’t predict any individual’s outcome. A 31% five-year survival rate for metastatic breast cancer means that roughly one in three people in that group were alive at the five-year mark, but some of those people lived much longer, and treatments available today weren’t available to everyone in that data set.
Several factors tilt the odds in a specific direction: younger age at diagnosis generally correlates with more aggressive biology but also better tolerance of treatment. Overall health, how well the cancer responds to its first line of treatment, and access to specialized cancer centers all matter. Genomic tests that analyze the tumor’s specific mutations can now help predict whether chemotherapy will add meaningful benefit for early-stage hormone receptor-positive cancers, allowing doctors to tailor treatment more precisely than the broad stage categories suggest.
The bottom line is that breast cancer survival has improved steadily over the past several decades and continues to improve. For the roughly 60% of women diagnosed with localized disease, the prognosis is excellent. For those with regional spread, the odds remain strongly favorable. And for metastatic disease, while the statistics are sobering, new treatments are extending survival in ways that weren’t possible even ten years ago.